A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Trial Profile

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Suspended
Phase of Trial: Phase II/III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Temozolomide (Primary) ; Veliparib (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Nov 2016 Status changed from recruiting to suspended.
    • 22 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top